Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mensa

Showing results (241-250 of 253) with videos related to

Pageof 26
Sort By:
Journal of Hepatology|November 5, 2019
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trialRobert S Brown, Maria Buti, Lino Rodrigues, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
The Lancet. Infectious Diseases|June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trialFrank Bähner, Saul N Faust, Leela R L Davies, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|March 6, 2021
Real-life use of remdesivir in hospitalized patients with COVID-19C Garcia-Vidal, F Meira, A Cózar-Llistó, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 5, 2023
Recommendations on the use of azole antifungals in hematology-oncology patientsJ R Azanza, J Mensa, J Barberán, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|October 25, 2021
Recommendations for antibiotic selection for severe nosocomial infectionsJ Mensa, J Barberán, R Ferrer, et al.
Infectious Diseases and Therapy|March 15, 2024
Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 VaccinationTimothy E Albertson, Caitlin Hansen, Smiti Bihari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
Pageof 26

Showing results (241-250 of 253) with videos related to

Sort By:
Pageof 26
Journal of Hepatology|November 5, 2019
Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trialRobert S Brown, Maria Buti, Lino Rodrigues, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without CirrhosisTarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
The Lancet. Infectious Diseases|June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trialFrank Bähner, Saul N Faust, Leela R L Davies, et al.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|March 6, 2021
Real-life use of remdesivir in hospitalized patients with COVID-19C Garcia-Vidal, F Meira, A Cózar-Llistó, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|April 5, 2023
Recommendations on the use of azole antifungals in hematology-oncology patientsJ R Azanza, J Mensa, J Barberán, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|October 25, 2021
Recommendations for antibiotic selection for severe nosocomial infectionsJ Mensa, J Barberán, R Ferrer, et al.
Infectious Diseases and Therapy|March 15, 2024
Serum Troponin I Assessments in 5- to 30-Year-Olds After BNT162b2 VaccinationTimothy E Albertson, Caitlin Hansen, Smiti Bihari, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 21, 2026
Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18‒55 Years OldPatricia Winokur, Oyeniyi Diya, David Fitz-Patrick, et al.
Pageof 26